STREPTASE 750000 I.U.

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

STREPTOKINASE

Pieejams no:

GENMEDIX , ISRAEL

ATĶ kods:

B01AD01

Zāļu forma:

POWDER FOR SOLUTION FOR INFUSION

Kompozīcija:

STREPTOKINASE 750000 IU/VIAL

Ievadīšanas:

I.V, INTRA-ARTERIAL

Receptes veids:

Required

Ražojis:

CSL BEHRING GmbH, GERMANY

Ārstniecības grupa:

STREPTOKINASE

Ārstniecības joma:

STREPTOKINASE

Ārstēšanas norādes:

Acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein.

Autorizācija datums:

2012-11-30

Produkta apraksts

_STREPTASE 750 000:_
STREPTASE
®
ACTIVE INGREDIENT: Stabilized pure streptokinase, derived from the
culture filtrate of beta-
haemolytic streptococci of Lancefield group C. It is presented as a
white powder and contains
stabilizers.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ACTIVE INGREDIENTS_
_STREPTASE 1 500 000:_
1 injection vial with 147 to 192 mg dried substance contains 1 500 000
IU streptokinase.
1 injection vial with 139 to 182 mg dried substance contains 750 000
IU streptokinase.
_OTHER INGREDIENTS_
Human albumin, Sodium-L-hydrogen glutamate monohydrate, Sodium
dihydrogenphosphate
dihydrate, Disodium hydrogenphosphate dihydrate.
PHARMACEUTICAL FORM AND PRESENTATIONS
_PHARMACEUTICAL FORM_
Powder for intravenous or intraarterial administration after
reconstitution with physiological saline.
_PRESENTATIONS_
Streptase 1 500 000
1 vial of 1 500 000 IU streptokinase
Streptase 750 000
1 vial of 750 000 IU streptokinase
PHARMACOTHERAPEUTIC GROUP
Streptokinase (antithrombotic agents, enzymes).
ATC-code: B01A D01
THERAPEUTIC INDICATIONS
Streptase 750,000 IU: Acute myocardial infarction, deep vein
thrombosis, pulmonary embolism,
acute or subacute thrombosis of peripheral arteries and chronic
occlusive arterial diseases,
occlusion of central retinal artery or vein.
Streptase 1,500,000 IU:
Systemic administration: in deep vein thromboses, lung embolism, acute
myocardial infarction for re-
opening of coronary vessels. In acute and subacute thromboses of
peripheral arteries and chronic
occlusive arterial diseases, occlusion of central retinal artery or
vein.
Local administration: in acute myocardial infarction for re-opening of
coronary vessels, in acute,
subacute and chronic thromboses as well as embolisms of peripheral
arteries.
CONTRAINDICATIONS
Streptase must not be used in case of severe allergic reactions to the
product.
Because of the increased risk of haemorrhage_ _under thrombolytic
therapy, Streptase must not be
given in the following situations:
−
existing or recent internal haemorrhages
−
all forms o